V. N. Fedorov

ORCID: 0009-0003-1296-1861
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Enzyme function and inhibition
  • Neurological Disorders and Treatments
  • Protease and Inhibitor Mechanisms
  • Cholinesterase and Neurodegenerative Diseases
  • Rheumatoid Arthritis Research and Therapies
  • Neurological Disease Mechanisms and Treatments
  • Signaling Pathways in Disease
  • Chemical synthesis and pharmacological studies
  • Biochemical effects in animals
  • Urticaria and Related Conditions
  • Phenothiazines and Benzothiazines Synthesis and Activities
  • Synthesis of Organic Compounds
  • Biotin and Related Studies
  • Chemical Reactions and Mechanisms

Yaroslavl State Medical Academy
2025

Yaroslavl State Pedagogical University
2023

Rheumatoid arthritis (RA) is a multifactorial incurable immune-inflammatory disease. Progression leads to joint deformation, cartilage and bone tissue destruction, subsequent disability. The primary goal of RA pharmacotherapy achieve disease remission. For this purpose, several classes drugs are used: basic anti-inflammatory (DMARDs), which large group synthetic biological that combined according their ability influence the pathogenetic mechanisms RA; glucocorticoids, recommended for use in...

10.37489/2588-0519-2024-4-4-14 article EN cc-by Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2025-01-17


 Introduction: Rheumatoid arthritis (RА) is an immune-inflammatory disease intrinsic to up 1.0% of the world’s population. Standard drugs for RA therapy are basic medications, glucocorticoids and non-steroid anti-inflammatory drugs, which often only ease or hinder course disease, not curing patient completely. Also, on average 20-50 % patients unresponsive treatment, allergic prescribed find them ineffective. That why medications with a different mechanism action being widely...

10.18413/rrpharmacology.9.10061 article EN cc-by Research Results in Pharmacology 2023-12-31

Introduction: Parkinson’s disease (PD) is a chronic neurodegenerative of the central nervous system, pathogenesis which associated with death dopaminergic neurons midbrain substantia nigra. The mainstay therapy for PD levodopa. However, in initial stages or case levodopa intolerance, MAO B inhibitors are used. Purpose study was to determine antiparkinsonian activity newly synthesized selective MAO-B vivo on model experimental parkinsonism white mice. Materials and Methods: Parkinsonian...

10.18413/rrpharmacology.10.540 article EN cc-by Research Results in Pharmacology 2024-12-30
Coming Soon ...